Harbin Pharmaceutical Group Co., Ltd. Class A 600664
SSE · China · Health Technology
CNY 7.40+0.26 (+3.64%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
MakklerAI · PRO
MakklerPRO is required for MakklerAI questions and forward scenarios grounded in structured data for the selected stock.
Upgrade to MakklerPROUpgrade to MakklerPRO to see the Makkler Fair Value calculation, the fundamental score and the multiples behind it.
Upgrade to MakklerPROUpgrade to MakklerPRO to see a 1-5 score for profitability, growth, cash-flow quality, and balance-sheet health.
Upgrade to MakklerPROUpgrade to MakklerPRO to see an AI-generated executive summary and bull/bear breakdown built from this stock's financial data.
Upgrade to MakklerPRO| Company | Market cap | P/E | P/B | P/S | Net margin | Revenue growth | Dividend yield | Beta |
|---|---|---|---|---|---|---|---|---|
| 600664Harbin Pharmaceutical Group Co., Ltd. Class A | CNY 18.64B | 36.4 | 3.1 | 1.1 | 3.2% | -0.1% | 0.0% | 0.4 |
| 600518Kangmei Pharmaceutical Co., Ltd Class A | CNY 18.48B | 638 | 2.5 | 3.7 | 0.6% | -5.6% | 0.0% | 0.6 |
| 600380Joincare Pharmaceutical Group Industry Co., Ltd. Class A | CNY 18.42B | 15.5 | 1.2 | 1.3 | 8.6% | -8.8% | 2.2% | 0.7 |
| 688428InnoCare Pharma Ltd. Class A | CNY 18.91B | 55.8 | 6.7 | 18.3 | 33.0% | 110.5% | 0.0% | 0.3 |
| 301301Yili Chuanning Biotechnology Co., Ltd. Class A | CNY 18.28B | 30.9 | 2.3 | 4.1 | 13.6% | -11.1% | 2.1% | 0.8 |
| 301047Sino Biological Inc. Class A | CNY 19.34B | 117 | 3.7 | 22.7 | 21.5% | 21.4% | 1.4% | 1.6 |
| 600511China National Medicines Corporation Ltd. Class A | CNY 19.69B | 10.2 | 1.0 | 0.4 | 3.6% | 4.1% | 3.1% | 0.5 |
| 002773Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A | CNY 20.08B | 20.1 | 2.2 | 4.8 | 23.2% | -6.5% | 3.2% | 0.7 |
| 300199Hybio Pharmaceutical Co., Ltd. Class A | CNY 20.34B | 165 | 24.8 | 18.2 | 11.6% | 25.3% | 0.0% | 2.4 |
| Peer median | 43.4 | 2.4 | 4.4 | 12.6% | -0.8% | 1.7% | 0.7 |
Peers are selected automatically from companies in the same industry. Extreme ratios (a loss-making company's P/E, or one distorted by a one-off item) are not adjusted away, which is why the summary row uses the median rather than the average. Not investment advice. The ratios in this table come from one outside provider for every company, so the comparison is internally consistent; they can differ from the filing-derived ratios higher up the page because the definitions differ.